Control of hyperphosphatemia beyond phosphate.
Hyperphosphatemia is a prevalent condition in the dialysis population and is associated with bad outcome. Block et al. present data from a post hoc analysis indicating that sevelamer, a noncalcium-containing phosphate binder, may confer a survival benefit in incident hyperphosphatemic hemodialysis patients. This is the first intervention study in the field of mineral metabolism showing a beneficial effect on a hard end point.
Evenepoel
P
P
Department of Medicine, Division of Nephrology, University Hospital Leuven, Leuven, Belgium. Pieter.Evenepoel@uz.kuleuven.ac.be
D002614:Chelating Agents / Q000627:therapeutic use*; D006801:Humans; D010710:Phosphates / Q000097:blood*; D010760:Phosphorus Metabolism Disorders / Q000209:etiology* / Q000517:prevention & control*; D011073:Polyamines / Q000627:therapeutic use*; D006435:Renal Dialysis / Q000009:adverse effects*; D000069603:Sevelamer
D002614:Chelating Agents; D010710:Phosphates; D011073:Polyamines; D000069603:Sevelamer